Vertex Pharmaceuticals Sublease Income remained flat by 0.0% to $50.00K in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 87.5%, from $400.00K to $50.00K. Over 2 years (FY 2023 to FY 2025), Sublease Income shows a downward trend with a -72.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Higher income indicates effective asset utilization and potential cost recovery from surplus capacity.
Revenue generated by leasing out portions of owned or leased assets to third-party tenants. This represents a recovery o...
Often seen in companies with significant real estate holdings or excess equipment capacity.
ibm_sublease_income| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $2.70M | $1.60M | $200.00K |
| YoY Change | — | -40.7% | -87.5% |